Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post